Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma

Real-time monitoring of drug efficacy in glioblastoma multiforme (GBM) is a major clinical problem as serial re-biopsy of primary tumours is often not a clinical option. MGMT (O(6)-methylguanine DNA methyltransferase) and APNG (alkylpurine-DNA-N-glycosylase) are key enzymes capable of repairing temozolomide-induced DNA damages and their levels in tissue are inversely related to treatment efficacy. Yet, serial clinical analysis remains difficult, and, when done, primarily relies on promoter methylation studies of tumour biopsy material at the time of initial surgery. Here we present a microfluidic chip to analyse mRNA levels of MGMT and APNG in enriched tumour exosomes obtained from blood. We show that exosomal…

• MG
  Massachusetts General Hospital
• MS
  Memorial Sloan-Kettering Cancer Center
• NI
  National Institutes of Health

  Awards: CA151884, W81XWH, CA069246, P01 CA069246, U19 CA179563, CA179563
• NO
  NIH Office of the Director

  Awards: P01 CA069246, U19 CA179563, CA179563
• NC
  National Cancer Institute

  Awards: CA069246, U54 CA151884, U19 CA179563, CA151884, P01 CA069246, CA179563
• OO
  Office of Strategic Coordination

  Award: U19 CA179563
• CF
  Common Fund